NCT04050085View on ClinicalTrials.gov

SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 15, 2019

Primary Completion Date

December 3, 2021

Study Completion Date

May 14, 2022

Conditions
Metastatic Pancreatic AdenocarcinomaRefractory Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
Interventions
BIOLOGICAL

Nivolumab

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

DRUG

TLR9 Agonist SD-101

Given intratumorally

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Dynavax Technologies Corporation

INDUSTRY

lead

University of California, Davis

OTHER